Heart Rhythm Society (HRS)

The Heart Rhythm Society (HRS) is the primary U.S. medical society for electrophysiology (EP). The organization promotes education and advocacy for cardiac arrhythmia professionals and patients, including setting policy guidelines and offering expert consensus.

Thumbnail

Could 2020 be the year of women in cardiology?

A number of female cardiologists are leading, or preparing to lead, top cardiology organizations this year. Could 2020 mean a paradigm shift for the field?

Thumbnail

HRS, CTA pen consumer guidelines for CV wearables

The Heart Rhythm Society and Consumer Technology Association will debut new consumer guidelines this week focused on wearables that detect and monitor cardiovascular metrics.

Thumbnail

The Rise of Wearables: What Experts Say About Patients, Platforms & Getting Paid

Cardiologists discuss the questions and concerns swirling around the thriving wearables market as patients strap on a variety of smart devices and expect their physicians to catch up.

Thumbnail

Andrea Russo inducted as HRS president

Cardiologist Andrea M. Russo, MD, took the reins of the Heart Rhythm Society as president this month after an induction ceremony at the organization’s annual meeting in San Francisco.

Thumbnail

HRS releases consensus statement on arrhythmogenic cardiomyopathy: 5 things to know

The Heart Rhythm Society issued a first-ever consensus statement on the evaluation, risk stratification and management of arrhythmogenic cardiomyopathy at its annual conference in San Francisco this spring.

Thumbnail

Program chair previews HRS.19 highlights

The Heart Rhythm Society's 2019 scientific sessions will be held May 8-11 in San Francisco, a venue that enabled the program committee to tap into Silicon Valley’s expertise with digital health, emerging technology and innovation. HRS.19 Program Director Christine Albert, MD, MPH, gave Cardiovascular Business a preview of meeting highlights.

Thumbnail

Patricia Blake named new CEO of Heart Rhythm Society

Patricia V. Blake will take over as CEO of the Heart Rhythm Society (HRS) next March, HRS leadership announced Oct. 26.

Study Shows Improved Quality of Life and Reduced Symptoms In Patients Treated with Medtronic Cryoballoon

DUBLIN and MUNICH — August 28, 2018 — Medtronic plc (NYSE:MDT) today announced new findings from the CRYO4PERSISTENT AF clinical trial demonstrating improved quality of life, reduced symptoms from abnormal heart rhythms, and low incidence of reinterventions and repeat ablation procedures.